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Abstract
Background: The aimwas to evaluate the analgesic efﬁcacy and safety of the dexketoprofen/tramadol 25 mg/75mg ﬁxed-dose
combination vs dexketoprofen (25 mg) and tramadol (100 mg) in moderate-to-severe acute pain after total hip arthroplasty.
Methods: This was a randomized, double-blind, parallel-group study in patients experiencing pain of at least moderate
intensity on the day after surgery, comparedwith placebo at ﬁrst administration to validate the painmodel. The study drugwas
administered orally every 8 h throughout a 5 day period. Rescue medication, metamizole 500 mg, was available during the
treatment period. The evaluation of efﬁcacy was based on patient assessments of pain intensity and pain relief. The primary
end point was the mean sum of the pain intensity difference values throughout the ﬁrst 8 h (SPID8).
Results: Overall, 641 patients, mean age 62 (range 29–80) yr, were analysed; mean () values of SPID8 were 247 (157) for
dexketoprofen/tramadol, 209 (155) for dexketoprofen, 205 (146) for tramadol, and 151 (159) for placebo. The primary analysis
conﬁrmed the superiority of the combination over dexketoprofen 25mg (P=0.019; 95% conﬁdence interval 6.4–73) and tramadol
100 mg (P=0.012; 95% conﬁdence interval 9.5–76). The single components were superior to placebo (P<0.05), conﬁrming model
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sensitivity. Most secondary analyses supported the superiority of the combination. The incidence of adverse drug reactionswas
low and similar among active treatment groups.
Conclusions: The efﬁcacy results conﬁrmed the superiority of dexketoprofen/tramadol over its single components, even at
higher doses (tramadol), with a safety proﬁle fully in line with that previously known for these agents in monotherapy.
Clinical trial registration: EudraCT 2012-004548-31 (https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_
number:2012-004548-31);
ClinicalTrials.gov NCT01902134 (https://www.clinicaltrials.gov/ct2/show/NCT01902134?term=NCT01902134&rank=1).
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Editor’s key points
• This study focuses on the efﬁcacy of combining a non-
steroidal anti-inﬂammatory drug with tramadol.
• Combining dexketoprofen and tramadol was effective, with
a reduction in required tramadol dose.
• Less rescue medication was used when dexketoprofen and
tramadol were combined.
• Adverse events were predictable from the known safety
proﬁle, although further studies are needed.
Despite the great variety of analgesics available, acute painman-
agement is still often inadequate.1–3 Possible causes include the
subjective nature of pain, incorrect diagnosis, or fear of adverse
drug reactions (ADRs).4
Combining different analgesics that act by different mechan-
isms (multimodal analgesia) to enhance clinical outcome is a
common strategy in pain management. Combinations do well
in single-dose analgesic studies,5 and there is a strong argument
for additivity of drug-speciﬁc beneﬁts.6 Some of the potential
beneﬁts of combinations include broader spectrum of action,
greater efﬁcacy, better compliance, complimentary pharmacoki-
netic proﬁle, and better efﬁcacy-to-safety ratio.7
Dexketoprofen, the active chiral formof ketoprofen, is effective
in acute pain8 in a wide variety of conditions,9 with an onset
of analgesic effect within 30 min.10 Tramadol is a widely used
opioid of proven efﬁcacy in combination with paracetamol.11
The combination of dexketoprofen/tramadol is expected to result
in additive analgesia, thus allowing a decrease in the required
doses of the single agents (particularly tramadol), and with the
beneﬁt of quick onset (typical of dexketoprofen) and long duration
(tramadol) of the analgesic effect. A previous dose-ﬁnding study
allowed for the selection of dexketoprofen/tramadol 25 mg/75
mg as the optimal combination of doses to be evaluated further.12
The present study was designed to demonstrate the superior
efﬁcacyof dexketoprofen/tramadol 25mg/75mgover the individ-
ual components (tramadol given at a higher dose) in moderate-
to-severe acute pain after total hip arthroplasty and to evaluate
its safety and tolerability.
Methods
Ethical approval
The study was conducted in accordance with the principles
of Good Clinical Practice and the Declaration of Helsinki, was
approved by all concerned Ethics committees, and was regis-
tered with EudraCT (2012-004548-31) and ClinicalTrials.gov
(NCT01902134). Written informed consent was obtained from
all patients. It was a multicentre, randomized, double-blind,
double-dummy, placebo- and active-controlled, parallel-group,
phase III study encompassing a single-dose phase (SDP) and a
multiple-dose phase (MDP). It was conducted at 37 study sites
in 10 countries (Czech Republic, Germany, Hungary, Latvia,
Lithuania, Poland, Serbia, Spain, Taiwan, and Ukraine) between
May 2013 and February 2014.
Patient population
The patients were men and women aged 18–80 yr, undergoing
standard primary unilateral total hip arthroplasty because of
osteoarthritis (excluding osteoarthritis secondary to systemic
or metabolic diseases, trauma, or infections) and experiencing
pain at rest of at least moderate intensity on the day after sur-
gery. Women participating in the study had to be either of
non-childbearing potential or willing to use a highly effective
contraceptive method.
Patients with known allergy or contraindication to the study
drugs or rescue medication (RM) were excluded from the study,
as were patients using and not able to stop analgesics other
than those speciﬁed in the protocol. Medications whose concomi-
tant use with the study drugs or RM were not advisable or might
confound the study results were restricted during pre-speciﬁed
time frames (related to drug characteristics such as half-life). Re-
stricted medications included monoamine oxidase inhibitors,
antiepileptics, antipsychotics, serotonin reuptake inhibitors, tri-
cyclic antidepressants, lithium, methotrexate, antibacterial sul-
phonamides, and ondansetron. Anticoagulants, thrombolytics,
and antiplatelet agents were also restricted, with the exception
of standard perioperative thromboprophylaxis and cardioprophy-
lactic use of low doses of aspirin (≤325 mg). Patients with moder-
ate to severe renal dysfunction, severe hepatic or severe cardiac
dysfunction, history of gastrointestinal disorders, bleeding disor-
ders, severe asthma, and epilepsy were excluded from participa-
tion in the study (according to the investigator’s judgement after
assessment of the medical history, physical examination, vital
signs, ECG, and laboratory safety tests at screening). Patients
with a history of drug or alcohol abuse, chronic opioid users (re-
cent use of major opioids or tramadol for more than 1 week),
and pregnant or breast-feeding women were also excluded.
Conduct of the study
Patients were enrolled at each site by the investigators according
to inclusion and exclusion criteria. The surgical procedure (includ-
ing the anaesthetic regimen) was performed in accordance with
the current site medical practice. Postoperative analgesia con-
sisted of i.v. or i.m. morphine or other short-acting opioids. The
dayafter surgery, 1 or 2h after cessation of postoperative analgesia
(dependingon route of administration), andprovided that patients
were capable of takingoralmedications, patientswhoexperienced
painof at leastmoderate intensity [deﬁnedaspain intensity visual
analog scale (PI-VAS) ≥40] were eligible to be randomized.
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Patients were assigned to one of six possible treatment arms
(A, B, C, D, E, or F) through an Interactive Voice/Web Response
(IVR/IWR) system after a computer-generated randomization se-
quence stratiﬁed by baseline PI-VAS categories [moderate pain
(40–60) and severe pain (>60)] with an imbalanced 1:3:1:3:1:3
ratio, using block size of 12].
The treatment arms determined the drugs to be received dur-
ing the SDP (relative to the ﬁrst 8 h after the ﬁrst study drug ad-
ministration) and the MDP (encompassing the 12 subsequent
doses, each one administered every 8 h) as represented in Table 1.
The overall study duration was ∼6 weeks for each patient, in-
cluding the screening period (within 4 weeks of the randomiza-
tion day), the treatment period (lasting 5 days), and the end-of-
study visit (1 week after the last dose) for ﬁnal safety follow-up.
Participants, health-care providers, and data collectors in-
volved in the conduct or statistical analysis were unaware of
the treatment that participants were receiving. Moreover, double-
blind conditions were secured by using a double-dummy design;
each study dose consisted of one tablet (containing dexketoprofen/
tramadol 25 mg/75 mg, dexketoprofen 25 mg, or placebo) and two
capsules (containing either tramadol 50 mg or placebo).
RM (metamizole 500mg, amaximum of four intakes per day)
was available during the entire treatment period, and the use
of paracetamol (500 mg) as antipyretic was allowed during
the MDP.
The evaluation of efﬁcacy was based on patients’ assessments
recorded in an electronic diary of the followingmeasures: pain in-
tensity (PI) at rest on a 0–100 visual analog scale (VAS; 0=no pain to
100=worst pain imaginable) at 30 min and 1, 1.5, 2, 3, 4, 6, and 8 h
post-dose (SDP) and every 2 h up to 8 h after the morning (seventh)
dose on day 3 (MDP); theworst PIwhilstmoving experienced during
the previous 24 h on a 0–100VAS (assessed 8 h after the correspond-
ingmorning dose on days 2 and 3); and pain relief (PAR) on a verbal
rating scale (VRS; 0=none to 4=complete) at 30min and 1, 1.5, 2, 3, 4,
6, and 8 h post-dose (SDP). The amount and the timewhen RMwas
used were also recorded.
Evaluation of safetywas based on the incidence, intensity, ser-
iousness, and causality of treatment-emergent adverse events
(AEs) and the frequency of clinically signiﬁcant changes in physic-
al examination, heart rate (HR), blood pressure (BP), laboratory
safety tests (haematology, biochemistry, and urinalysis), and
12-lead ECG.
Outcomes
The primary efﬁcacy outcome was the mean sum of pain inten-
sity differences (SPID) throughout 8 h after the ﬁrst dose (SPID8
corresponds to the area under the pain intensity difference vs
time curve during 8 h post-dose).
Secondary PI-related end points during the SDP and MDP in-
cluded the following: mean PI-VAS scores, mean SPID at rest,
mean percentage of theoretical maximum SPID (% max SPID)
at rest, percentage of PI responders (achievement of a mean
PI-VAS <40 at rest), and worst pain on movement. The PAR-re-
lated end points over SDP included the following: mean PAR-
VRS scores, mean total pain relief (TOTPAR), and percentage
of TOTPAR responders (achievement of at least 50% of theoret-
ical maximumTOTPAR; ≥50%max TOTPAR). The use of RMwas
also studied.
Statistics
The null hypothesis of equality between dexketoprofen/trama-
dol and each single component was tested as co-primary efﬁcacy
end points using an analysis of covariance () and a two-
sided overall signiﬁcance level of 5%. The two covariates were
treatment (main effect) and baseline PI category.
The analysis of the primary end point was also carried out for
sensitivity purposes in all randomized patients without any im-
putation and in all patients without major protocol violations.
The PI-VAS, SPID, % max SPID, and TOTPAR were analysed
analogously. The PAR-VRS were analysed by Wilcoxon rank-
sum test.
The percentage of responders was analysed using a χ2 test. In
addition, the percentage of PI responders throughout 8 h post-
dose was analysed using a general estimating equations (GEE)
analysis.
The number of patients using RMwas analysed using a χ2 test.
Safety variables were analysed bymeans of descriptive statistics.
All report outputswere producedusingSAS version9.2 (SAS In-
stitute Inc., Cary, NC, USA) in a secure and validated environment.
For the primary analysis, single missing values were linearly
interpolated. A last observation carried forward (LOCF) approach
was used formultiple consecutivemissing values, unless the rea-
son for amissing valuewas sleep (reported in the subsequent as-
sessment), in which case this last missing value was replaced by
the lowest PI-VAS from the relevant 8 h period.
In order tominimize the impact of RM (or paracetamol as anti-
pyretic during MDP) on the efﬁcacy assessments, the PI and PAR
scores recorded for 6 h after RM intake were replaced using the
baseline observation carried forward (BOCF) during the SDP13
and the LOCF during the MDP [or worst observation carried for-
ward (WOCF) if the assessment immediately before RM intake
was missing].
Sample size calculation
A sample size of 600 patients and a signiﬁcance level of 0.05 were
required for a power higher than 85% to detect the differences
in change of SPID8 between dexketoprofen/tramadol and each
single component.
A standard deviation of 94 mm hand a between difference of at
least 35 mmhwasassumedbasedondata fromaprevious phase II
study (Scartoni S and Nizzardo A, unpublished observations). As-
suming an approximate 25% screening failure rate, 800 patients
would need to be screened.
Results
A total of 641 patients were randomized to one of six possible
treatment arms. The participant ﬂow, with the numbers of
Table 1 Treatment arms
Group
assignment
Single-dose phase Multiple-dose phase
A Placebo Dexketoprofen/
tramadol 25 mg/
75 mg
B Dexketoprofen/
tramadol 25 mg/
75 mg
Dexketoprofen/
tramadol 25 mg/
75 mg
C Placebo Dexketoprofen 25 mg
D Dexketoprofen 25 mg Dexketoprofen 25 mg
E Placebo Tramadol 100 mg
F Tramadol 100 mg Tramadol 100 mg
Oral dexketoprofen/tramadol combination in acute pain | 271
 at U
niversity of D
ebrecen, Faculty of M
edicine, Central Library on A
pril 7, 2016
http://bja.oxfordjournals.org/
D
ow
nloaded from
 
participants who were randomly assigned and received the in-
tended treatment and were analysed for the primary outcome,
is represented in Fig. 1. All randomized patients were included
in the efﬁcacy and safety analysis.
The mean age of the patients was 62 (range 29–80) yr, with a
balanced gender distribution (295 males and 346 females). Base-
line pain was moderate (PI-VAS 40–60 mm) in 324 patients (51%)
and severe (>60 mm) in 315 (49%). Patient characteristics and
baseline data were comparable among different treatment arms
(Supplementary material, Table S1).
For the analyses pertinent to the SDP, treatment arms were
combined to produce the following four groups: dexketoprofen/
tramadol (B=159); dexketoprofen (D=161); tramadol (F=160); and
placebo (A+C+E=161). During the MDP, treatment arms including
the same active treatment were combined, resulting in the fol-
lowing three groups: dexketoprofen/tramadol (A+B=213); dexke-
toprofen (C+D=214); and tramadol (E+F=214).
Overall, 93 (14.5%) patients had major protocol deviations
during the study. Most common major protocol deviations
were related to use of restricted or prohibited medication
Enrolm
ent
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Allocation
m
ultiple-dose phase
F
ollo
w
-up
F
ollo
w
-up
Analysis
populations
Excluded
(n=105)
Allocated to
treatment A (n=54)
Allocated to
treatment B (n=159)
Allocated to
treatment C (n=53)
Allocated to
treatment D (n=161)
Allocated to
treatment E (n=54)
Allocated to
treatment F (n=160)
Allocated to
DKP/TRAM
(n=54)
Allocated to
DKP/TRAM
(n=159)
Allocated to DKP
(n=53)
Allocated to DKP
(n=160)
Allocated to TRAM
(n=52)
Allocated to TRAM
(n=160)
Discontinued (n=0)
Placebo (n=54)
Received alloc
(n=54)
Not received alloc
(n=0)
Placebo (n=53)
Received alloc
(n=53)
Not received alloc
(n=0)
DKP/TRAM (n=159)
Received alloc
(n=159)
Not received alloc
(n=0)
Placebo (n=54)
Received alloc
(n=54)
Not received alloc
(n=0)
TRAM (n=160)
Received alloc
(n=160)
Not received alloc
(n=0)
DKP (n=161)
Received alloc
(n=161)
Not received alloc
(n=0)
DKP/TRAM
Received alloc
(n=54)
Not received alloc
(n=0)
DKP
Received alloc
(n=53)
Not received alloc
(n=0)
DKP/TRAM
Received alloc
(n=159)
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(n=0)
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Received alloc
(n=160)
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(n=0)
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(n=160)
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(n=0)
Placebo +
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ITT (n=54)
Safety (n=54)
PP (n=45)
Placebo + DKP
ITT (n=53)
Safety (n=53)
PP (n=46)
DKP/TRAM +
DKP/TRAM
ITT (n=159)
Safety (n=159)
PP (n=142)
Placebo + TRAM
ITT (n=54)
Safety (n=54)
PP (n=45)
TRAM + TRAM
ITT (n=160)
Safety (n=160)
PP (n=129)
DKP + DKP
ITT (n=161)
Safety (n=161)
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- Withdrawal by
subject (n=1)
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(n=1)
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- Adverse event
(n=3)
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with study drug
(n=1)
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- Withdrawal by
subject (n=1)
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Assessed for
eligibility
(n=746)
Randomized
(n=641)
Fig 1 Study CONSORT ﬂow diagram. Participant ﬂow, with the numbers of participants who were randomly assigned, received intended treatment, and were
analysed for the primary outcome. Analysis populations were as follows: the ITT population included all patients randomized; the safety population included
all patients randomized who received at least one dose of study treatment; and the PP population included all ITT patients with no major protocol violations.
•, received at least one dose; alloc., allocated; DKP, dexketoprofen trometamol 25 mg; DKP/TRAM, dexketoprofen trometamol/tramadol hydrochloride
25 mg/75 mg; ITT, intention to treat; n, number of patients; PP, per protocol; TRAM, tramadol hydrochloride 100 mg.
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(34) or study procedures (34), with a potential impact on both
SDP and MDP.
Single-dose phase
For the primary end point, SPID8, the highestmean () valuewas
reported in the dexketoprofen/tramadol group [247 (157)]; values
reported by dexketoprofen and tramadol groups were very
similar, [209 (155)] and [205 (146)], respectively, and the lowest
value was reported in the placebo group [151 (159)]. The combin-
ation was signiﬁcantly better than dexketoprofen [P=0.019; 95%
conﬁdence interval (CI) 6.4–73] and tramadol (P=0.012; 95% CI
9.5–76). Active treatments were superior to placebo (P<0.05),
thus conﬁrming model sensitivity. The analysis in all rando-
mized patients without any imputation conﬁrmed these results.
In the analysis of all patients without major protocol violations
(n=548), the differences between dexketoprofen/tramadol and
both single components did not reach statistical signiﬁcance
at the 5% level (Table 2).
Analysis of PI-VAS scores at rest (Fig. 2 and Supplementary
material, Table S2), mean SPID at rest (Table 3), and mean %
max SPID at rest (Supplementary material, Table S3) during the
SDP conﬁrmed in general the superiority of dexketoprofen/
tramadol over dexketoprofen and tramadol from the 3 and 4 h
time point onwards.
In the dexketoprofen/tramadol group, 77%were PI responders
(mean PI-VAS <40) at the 8 h time point of the SDP, in comparison
to 67% in the dexketoprofen group (P=0.055), 66% in the tramadol
group (P=0.029), and 50% for placebo. Both single components
had a signiﬁcantly higher response than placebo (P<0.05 for
both comparisons). The results of the GEE analysis showed the
superiority of the combination over both dexketoprofen
(P=0.012, 95% CI 1.1–2.5) and tramadol (P=0.039, 95% CI 1.0–2.3),
and conﬁrmed the superiority of dexketoprofen and tramadol
over placebo (P=0.001, 95% CI 1.3–2.7 and P<0.001, 95% CI
1.4–3.0, respectively).
In terms of mean TOTPAR and percentage of TOTPAR respon-
ders (at least 50% max TOTPAR) at the end of the SDP, the higher
values were observed in the dexketoprofen/tramadol group, but
the differences did not reach statistical signiﬁcance (Supplemen-
tary material, Table S4).
Multiple-dose phase
Analysis of PI-VAS scores at rest (Fig. 3 and Supplementary ma-
terial, Table S2), mean SPID at rest (Table 3), and mean % max
SPID at rest (Supplementary material, Table S3) during the MDP
conﬁrmed in general the superiority of dexketoprofen/tramadol
over dexketoprofen and tramadol throughout 48 h (for mean
SPID, the superiority of the combination over tramadol ap-
proached statistical signiﬁcance).
The use of RM, deﬁned as the percentages of patients using
RM during 24 and 48 h and overall during the MDP, were lower
in the dexketoprofen/tramadol group (7.0, 8.9, and 11%, respect-
ively) than in the dexketoprofen group (17, 24, and 29%, respect-
ively) and in the tramadol group (19, 22, and 23%, respectively).
These differences were statistically signiﬁcant throughout all
time points (all P≤0.001).
Mean () scores for worst pain whilst moving during the pre-
vious 24 h (days 2 and 3)were slightly lower in the dexketoprofen/
tramadol group (29 [21] and 24 [19], respectively) than in the dex-
ketoprofen group (34 [24] and 28 [22], respectively) and the trama-
dol group (33 [22] and 27 [20], respectively).
Safety results
Of the 641 patients randomized and dosed, 27 (4.2%) patients ex-
perienced a total of 39ADRs during the active treatment, ofwhich
16 were mild, 18 were moderate, and ﬁve were severe. The most
frequent ADRs (≥1% amongst the treatment group) were nausea
(0.9% patients; six events) and vomiting (0.6% patients; four
events).
The dexketoprofen/tramadol group presented a lower inci-
dence of ADRs (2.8% of patients) in comparisonwith the dexketo-
profen group (4.7% of patients) and the tramadol group (5.1% of
patients).
Table 2 Statistical analysis of SPID8 at rest (analysis of covariance). DKP, dexketoprofen trometamol 25 mg; DKP/TRAM, dexketoprofen
trometamol/tramadol hydrochloride 25 mg/75 mg; , standard error; SPID8, sum of the pain intensity differences throughout 8 h after the
ﬁrst dose; TRAM, tramadol hydrochloride 100 mg
Population Point estimate ()
(Treatment A)
Point estimate ()
(Treatment B)
Estimated difference ()
(Treatment A−B)
95% Conﬁdence
interval
P-value
Treatment A Treatment B
All randomized patients
DKP/TRAM DKP 248 (12) 208 (12) 39 (17) 6.4–73 0.019
DKP/TRAM TRAM 248 (12) 205 (12) 43 (17) 9.5–76 0.012
DKP Placebo 208 (12) 152 (12) 57 (17) 24–90 <0.001
TRAM Placebo 205 (12) 152 (12) 54 (17) 21–87 0.002
All randomized patients with no imputations
DKP/TRAM DKP 243 (11) 207 (11) 36 (16) 4.7–68 0.024
DKP/TRAM TRAM 243 (11) 208 (11) 35 (16) 3.7–67 0.029
DKP Placebo 207 (11) 170 (11) 37 (16) 5.0–68 0.023
TRAM Placebo 208 (11) 170 (11) 38 (16) 6.1–69 0.020
All patients with no major protocol violations
DKP/TRAM DKP 251 (13) 222 (13) 29 (18) −6.0 to 64 0.104
DKP/TRAM TRAM 251 (13) 217 (13) 33 (18) −2.5 to 69 0.068
DKP Placebo 222 (13) 156 (13) 66 (18) 30–101 <0.001
TRAM Placebo 217 (13) 156 (13) 61 (18) 25–97 <0.001
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Two patients reported a total of ﬁve serious ADRs. One patient
in the dexketoprofen group experienced duodenal ulcer. Another
patient in the dexketoprofen/tramadol group experienced perior-
bital oedema, face oedema, laryngeal oedema, and haematuria.
These events were resolved on the same day (haematuria
resolved within 2 days).
There were no marked differences between treatment groups
in terms of safety outcomes, including HR, BP, physical examin-
ation, 12-lead ECG, or laboratory safety parameters.
Discussion
The present study was conducted in a model of moderate-
to-severe acute nociceptive somatic pain (major orthopaedic
surgery) regarded as clinically relevant by regulators4 and
prescribing physicians.14
The design was primarily aimed at testing the superior
efﬁcacy of dexketoprofen/tramadol vs the single agents during
the SDP (primary end point), whereas the MDP was intended to
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Fig 2 Observed PI-VAS at rest for the single-dose phase (ﬁrst 8 h) by treatment (all randomized patients). DKP, dexketoprofen trometamol 25 mg; DKP/TRAM,
dexketoprofen trometamol/tramadol hydrochloride 25 mg/75 mg; PI, pain intensity; PI-VAS, pain intensity visual analog scale; TRAM, tramadol hydrochloride
100 mg; VAS, visual analog scale.
Table 3 Statistical analysis of SPID at rest during 2, 4, 6, 24, and 48 h (analysis of covariance; all randomized patients). DKP, dexketoprofen
trometamol 25 mg; DKP/TRAM, dexketoprofen trometamol/tramadol hydrochloride 25mg/75mg; , standard error; SPIDn, sum of the pain
intensity differences during ‘n’ hours after the ﬁrst dose; TRAM, tramadol hydrochloride 100 mg
Time points Point estimate ()
(Treatment A)
Point estimate
() (Treatment B)
Estimated treatment
difference ()
(Treatment A−B)
95% Conﬁdence
interval
P-value
Treatment A Treatment B
SPID2 at rest
DKP/TRAM DKP 52 (2.7) 44 (2.7) 7.9 (3.8) 0.4–16 0.038
DKP/TRAM TRAM 52 (2.7) 47 (2.7) 5.7 (3.8) −1.8 to 13 0.136
DKP Placebo 44 (2.7) 40 (2.7) 4.1 (3.8) −3.4 to 12 0.282
TRAM Placebo 47 (2.7) 6.4 (3.8) 6.4 (3.8) −1.2 to 14 0.097
SPID4 at rest
DKP/TRAM DKP 124 (5.8) 103 (5.8) 22 (8.2) 5.9–38 0.008
DKP/TRAM TRAM 124 (5.8) 105 (5.8) 19 (8.2) 3.2–35 0.019
DKP Placebo 103 (5.8) 85 (5.8) 18 (8.2) 1.7–34 0.030
TRAM Placebo 105 (5.8) 85 (5.8) 20 (8.2) 4.4–36 0.013
SPID6 at rest
DKP/TRAM DKP 191 (8.9) 158 (8.8) 33 (13) 8.1–57 0.009
DKP/TRAM TRAM 191 (8.9) 159 (8.8) 32 (13) 7.5–57 0.011
DKP Placebo 158 (8.8) 120 (8.8) 38 (13) 14–63 0.002
TRAM Placebo 159 (8.8) 120 (8.8) 39 (13) 14–63 0.002
SPID24 at rest
DKP/TRAM DKP 929 (34) 752 (34) 177 (48) 82–271 <0.001
DKP/TRAM TRAM 929 (34) 827 (34) 102 (48) 8.1–197 0.033
SPID48 at rest
DKP/TRAM DKP 1949 (65) 1674 (65) 274 (92) 93–455 0.003
DKP/TRAM TRAM 1949 (65) 1771 (65) 178 (92) −2.8 to 359 0.054
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conﬁrm the sustained efﬁcacy of the combination (during the
ﬁrst 48 h of the MDP) and to establish its safety during the re-
peated administration (up to day 5). It was deemed that evalua-
tions of efﬁcacy beyond this point would not provide the same
degree of assay sensitivity because of the inherent increased
variability and because postoperative pain usually decreases
with time owing to thenormal course of healing, and pain control
may become less distinguishable.15 16
The surgical technique and anaesthetic regimen were not
standardized in the study because local standards for surgical
technique andanaesthesia represent the best patientmanagement
available at each site. Potential surgical confounders were re-
duced by selecting only patients undergoing primary (ﬁrst time)
unilateral total hip arthroplasty because of primary osteoarth-
ritis. Other important factors, such as the postoperative analgesic
care, were standardized, and only those patients experiencing a
certain level of pain intensity on the day after surgery were
included in the study.
Given that early mobilization is crucial after hip arthroplasty,
pain onmovement was assessed on days 2 and 3 bymeans of the
‘worst pain whilst moving experienced during the previous 24 h’.
The limited value of these results is acknowledged but, owing to
the study characteristics, pain onmovement could not have been
measured on day 1 (patients could have received different treat-
ments during this period). Moreover, other procedures to meas-
ure pain on movement, such as pain evoked by a standardized
manoeuvre, might be more precise because a recall effect is
avoided, but they are hardly feasible in such a well-sampled
study considering the variability in strategies for early mobiliza-
tion after total hip arthroplasty.
The results of the present study conﬁrmed that dexketopro-
fen/tramadol 25 mg/75 mg oral ﬁxed-dose combination was
able to provide analgesic efﬁcacy greater than was achieved
with each component in monotherapy, one of them adminis-
tered at a higher dose than in the combination (tramadol 100
mg). The efﬁcacy results were consistent after single- and mul-
tiple-dose administration, thus supporting the selection of the
doses and the posology (dosing) proposed according to the previ-
ous phase II dose-ﬁnding study.12 The fact that the sensitivity
analysis of the primary end point including all patients without
major protocol violations did not reach statistical signiﬁcance
was possibly related to the reduction in the overall number of
patients.
Regarding safety, results showed no increase of ADRswith the
ﬁxed-dose combination over the single agents. Most of the ser-
ious ADRs reported in the dexketoprofen/tramadol-treated pa-
tients are already described in dexketoprofen Summary of
Product Characteristics [and also associated with other non-ster-
oidal anti-inﬂammatory drugs (NSAIDs)] with a low frequency, as
follows: laryngeal oedema (rare=0.01–0.1%) and face andperiorbi-
tal oedema (angioedema, facial oedema; very rare/isolated re-
ports ≤0.01%). Angioneurotic oedema is also associated with
tramadol (rare=0.01–0.1%). The serious ADR haematuria could
plausibly be attributed to other concomitant treatments (rivarox-
aban) received by the patient.
Nevertheless, safety results should be considered cautiously
because the study, being primarily intended to assess the short-
term analgesic efﬁcacy of dexketoprofen/tramadol, lacks the
power fully to assess speciﬁc risks, for instance those asso-
ciated with the use of NSAIDs, such as cardiovascular, renal,
and gastrointestinal bleeding. Moreover, the study population
was selected according to the current restrictions for the sin-
gle components because all precautions for use applicable for
the single agents remain applicable to the combination.
In particular, non-selective NSAIDs should be used with cau-
tion in the postoperative setting because the antiplatelet ef-
fect may result in an increase of perioperative blood loss.17
18 Likewise, clinical trial and epidemiological data suggest
that use of some NSAIDs may be associated with an increased
risk of arterial thrombotic events.19 Consequently, patients
with risk factors for cardiovascular disease (such as uncon-
trolled hypertension, congestive heart failure, established
ischaemic heart disease, peripheral arterial disease, or cere-
brovascular disease) should be treated with NSAIDs only
after careful consideration.
In conclusion, the study results provided robust evidence of
the efﬁcacy of dexketoprofen/tramadol ﬁxed-dose combination
in the management of moderate-to-severe acute pain, with a
safety proﬁle fully in line with that previously known for the
single agents in monotherapy.
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